玻璃酸钠滴眼液成功获批，扬州中宝药业眼科管线再添新动力

Core Insights - The National Medical Products Administration has approved the sodium hyaluronate eye drops submitted by Yangzhou Zhongbao Pharmaceutical Co., Ltd, enhancing the company's product pipeline in the ophthalmology sector [1][2] - Sodium hyaluronate is a natural polysaccharide known for its excellent moisture retention and lubrication properties, addressing the increasing prevalence of dry eye symptoms due to heightened screen time and electronic device usage [1] - The approval of this product not only provides a reliable solution for the domestic eye medication market but also offers consumers a convenient and safe option for self-medication [1] Company Overview - Yangzhou Zhongbao Pharmaceutical is a comprehensive pharmaceutical enterprise engaged in research and development, production, and marketing, with a product range covering cardiovascular, respiratory, ophthalmology, and health sectors [1] - The company has established a diversified R&D system, including innovative drug development, inhalation formulation technology platforms, and ophthalmic drug research platforms, showcasing its continuous innovation capabilities [1] - The company has received over 20 invention patent authorizations and has more than 30 ongoing projects, reflecting its robust innovation vitality [1] Recent Developments - In the past two years, Yangzhou Zhongbao Pharmaceutical has entered a concentrated harvest period for R&D achievements, with multiple new products successfully launched or passing the consistency evaluation for generic drugs [2] - The sodium hyaluronate eye drops are not the only product approved this year; the company has also received approvals for six other products, including inhalation solutions and injection liquids, demonstrating strong product pipeline development and continuous innovation [2] - Looking ahead, the company plans to leverage this product approval to increase R&D investment, optimize product structure, and develop more high-quality drugs that meet clinical and market needs, contributing to the "Healthy China" initiative [2]